专利检索 ap:("Serafino Pantano" OR "Fang Li" OR "Nanxin Li" OR "Anthony Boral") AND inv:"Serafino Pantano" 第 1 页

1.

发明申请
Combination of Ceritinib with an EGFR Inhibitor 审中-公开

公开(公告)号：US20170252335A1

公开(公告)日：2017-09-07

申请号：US15519593

申请日：2015-10-15

申请人： Serafino Pantano , Fang Li , Nanxin Li , Anthony Boral

发明人： Serafino Pantano , Fang Li , Nanxin Li , Anthony Boral

IPC分类号： A61K31/4706 , A61K31/4709 , A61K31/506 , C07K16/32 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K39/395 , A61K31/517

CPC分类号： A61K31/4706 , A61K31/4709 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2300/00 , C07K16/32

摘要： The present disclosure relates to a pharmaceutical composition comprising two Tyrosine Kinase Inhibitors (TKIs), namely Ceritinib and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of a TKI mediated disease, such as cancer. The disclosure also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.